ReviewTrends in endocrinology and metabolism: TEM2011
Progesterone: the ultimate endometrial tumor suppressor.
Review in Trends in endocrinology and metabolism: TEM, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 5 syntheses or guidelines pooled it, 187 citations in OpenAlex.
- Metformin for endometrial hyperplasia.The Cochrane database of systematic reviews · 2024Pooled it
- Metformin for endometrial hyperplasia.The Cochrane database of systematic reviews · 2017Pooled it
- Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis.World journal of surgical oncology · 2015Pooled it
- Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients: a meta-analysis.International journal of clinical and experimental pathology · 2014Pooled it
- Quantitative assessment of the association between CYP1A1 A4889G polymorphism and endometrial cancer risk.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Pooled it
- A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Trial
- Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial.Journal of the National Cancer Institute · 2016Trial
- Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study.International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 2014Trial
- Primate-specific melanoma antigen-A11 regulates isoform-specific human progesterone receptor-B transactivation.The Journal of biological chemistry · 2012Trial
- Article
- Review
- Hormonal Dysregulation and Neuroinflammation in Endometriosis: Convergent Druggable Pathways.Current issues in molecular biology · 2026Review
- Targeting Apoptosis-Resistant Proliferation: Imatinib-Based Combinations Induce Durable Cytostatic Arrest in 3D Endometrial Cancer Spheroids.Biomedicines · 2026Article
- Short-term hormonal modulation with mifepristone does not induce oncogenic changes in the endometrium of BRCA1/2 pathogenic variant carriers.Communications medicine · 2026Article
- FOXA2 sensitizes endometrial carcinoma to progestin-mediated conservative therapy by triggering PR transcriptional activation.Oncogene · 2025Article
- Advances in the molecular mechanisms underlying progestin resistance in endometrial cancer.Fundamental research · 2025Review
- Epigenetic Therapies in Endocrine-Related Cancers: Past Insights and Clinical Progress.Cancers · 2025Review
- Bioprinted Hormone-Responsive Bilayer Model of Human Endometrium for Embryo Implantation Studies.ACS biomaterials science & engineering · 2025Article
- UterineCancers · 2025Article
- Enhancing Progestin Therapy with a Glucagon-Like Peptide 1 Agonist for the Conservative Management of Endometrial Cancer.Cancers · 2025Article
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The uterine endometrium is exquisitely sensitive to steroid hormones that act through well-described nuclear receptors. Estrogen drives epithelial proliferation, and progesterone inhibits growth and causes cell differentiation. The importance of progesterone as a key inhibitor of carcinogenesis is reflected by the observation that women who ovulate and produce progesterone almost never get endometrial cancer. In this review we describe seminal research findings that define progesterone as the major endometrial tumor suppressor. We discuss the genes and diverse signaling pathways that are controlled by progesterone through progesterone receptors (PRs) and also the multiple factors that regulate progesterone/PR activity. By defining these progesterone-regulated factors and pathways we identify the principal therapeutic opportunities to control the growth of endometrial cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.